Drug Type Bispecific antibody, Enzyme |
Synonyms- |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), Hyaluronic acid modulators, c-Met inhibitors(Hepatocyte growth factor receptor inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-Small Cell Lung Cancer | NDA/BLA | US | 17 Jun 2024 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | US | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | JP | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AR | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | AU | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | BR | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CA | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | FR | 05 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | DE | 05 Aug 2022 |